Physician profile
Stephen E Garcia
NPI 1285721647
$797.41
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $196 · 2021: $136 · 2022: $176.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $131.14 | 2019-2022 | |
| Vifor Pharma, INC. | $103.76 | 2019-2022 | |
| Amgen INC. | $91.75 | 2019-2022 | |
| Travere Therapeutics, INC. | $62.40 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $56.09 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $54.63 | 2020 | |
| Daiichi Sankyo INC. | $50.33 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $39.93 | 2020-2022 | |
| Fresenius USA Marketing, INC. | $32.69 | 2019-2020 | |
| Glaxosmithkline, LLC. | $25.45 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $22.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.84 | 2022 | |
| Baxter Healthcare | $21.80 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.43 | 2019 | |
| Horizon Therapeutics Plc | $20.52 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $15.25 | 2020 | |
| Opko Pharmaceuticals, LLC | $14.83 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $11.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.